6 Overstated
Dietary fiber is the nutrient responsible for maintaining gut function.
"Did you know your gut controls your energy, your recovery, how well you absorb everything that you eat, and the one nutrient that keeps it all running properly is fiber?" (said at 0:24:02)
Dietary fiber plays a well-established and essential role in maintaining gastrointestinal health, regulating transit time, supporting stool formation, and feeding commensal gut microbiota that produce beneficial short-chain fatty acids. However, claiming that fiber is 'the one nutrient' that keeps gut function running properly is an overstatement. Optimal gut function, mucosal barrier integrity, epithelial turnover, and nutrient absorption depend on a wide array of macro- and micronutrients, including amino acids (such as glutamine), essential fatty acids, zinc, and vitamins, alongside adequate hydration.
Clinical trials on AG1 NextGen demonstrated that it fills common nutrient gaps and improves key nutrient levels within 3 months.
"backed by four clinical trials. And in those trials, it was shown to fill common nutrient gaps, improve key nutrient levels in just 3 months" (said at 0:58:47)
Published randomized clinical trials on AG1 have evaluated nutrient absorption and adequacy, but the evidence is more limited in sample size and duration than claimed. A double-blind, randomized crossover trial in 20 resistance-trained adults found that 14 days of AG1 supplementation improved dietary micronutrient adequacy by increasing the number of Estimated Average Requirements (EARs) met, most notably for vitamins A, C, and E. Additionally, a pharmacokinetic crossover trial in 16 adults demonstrated acute absorption (over 8 hours) for multiple vitamins and minerals. However, published trials are short-term (hours to 2–4 weeks) with very small sample sizes (n = 16–30), rather than large 3-month trials establishing clinical reversal of nutrient deficiencies.
Clinical trials on AG1 NextGen showed it increases healthy gut bacteria by 10 times, even in people who already eat well.
"and increase healthy gut bacteria by 10 times, even in people who already eat well." (said at 0:58:57)
A randomized, double-blind, placebo-controlled crossover trial evaluated the effects of 14 days of AG1 supplementation on gut microbiota in 20 healthy, resistance-trained adults. The study found that AG1 did not produce large global shifts in overall microbial alpha or beta diversity, though it was associated with selective enrichment of specific probiotic taxa (such as Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus, and Bifidobacterium animalis). While marketing statements have extrapolated substantial fold-increases in specific probiotic strains from preliminary or in vitro model data, clinical trials in humans do not demonstrate a generalized 10-fold increase across healthy gut bacteria.
AG1 NextGen is backed by four clinical trials.
"And now they've taken it a step further with AG1 NextGen, backed by four clinical trials." (said at 0:58:47)
The claim that AG1 NextGen is backed by four clinical trials overstates the existing published clinical trial evidence for the product. Published peer-reviewed literature documents three clinical trials evaluating AG1 (PMID: 42518997, PMID: 41988471, PMID: 39352252). A fourth published study evaluating AG1's effects on age-related mobility was conducted in *C. elegans* roundworms, not humans (PMID: 42365207). While human clinical trials demonstrate absorption of vitamins and minerals (PMID: 42518997), improved nutrient adequacy, and selective enrichment of specific probiotic gut taxa (PMID: 41988471, PMID: 39352252), describing all supporting research as four clinical trials overstates the number of human trials present in the published record.
- supports: The effects of AG1® supplementation on the gut microbiome of healthy adults: a random… (Journal of the International Society of Sports Nutrition 2024) · cited 5x in the literature
"Using a double-blind, randomized, two-arm, placebo-controlled, parallel design, we examined a 4-week daily supplementation regimen of AG1 ® vs. placebo (PL)." (abstract, methods)
pubmedfull study (doi) - supports: Effect of AG1 ® supplementation on nutritional adequacy and gut microbial composition… (Frontiers in nutrition 2026)
"This randomized, double-blind, placebo-controlled crossover study examined the effects of two weeks of the nutritional supplement (AG1 ® ) on gut microbial composition, nutritional adequacy, and tolerability." (abstract, methods)
pubmedfull study (doi) - contradicts: A multi-ingredient food supplement slows age-dependent decline of mobility and influences … (Biogerontology 2026)
"We therefore employed C. elegans as a rapidly ageing model organism to investigate the effects of two commercially available nutrition-based products on ageing-related decline of mobility as an indication of healthspan." (abstract, background)
pubmedfull study (doi) - supports: Absorption kinetics of vitamins and minerals from a novel nutritional product in physicall… (Frontiers in nutrition 2026)
"In a randomized, double-blind, placebo-controlled crossover trial 16 healthy adults (8 males and 8 females) consumed a single serving (13 g) of AG1 or a taste- and appearance-matched placebo mixed in water, following a 10-h overnight fast." (abstract, methods)
pubmedfull study (doi)
BPC-157 aids in tissue recovery and gut health.
"Anyway, BPC-157, TB-500, Thymosin Alpha, and SS-31. So, recovery and gut" (said at 1:39:48)
The host's statement implies that BPC-157 is an established therapeutic agent for tissue recovery and gut health. While preclinical animal models and in vitro studies show that BPC-157 promotes angiogenesis, collagen synthesis, and mucosal healing across gastrointestinal and musculoskeletal tissues, robust human clinical trial evidence proving efficacy and safety in humans is lacking. Human data remain restricted to small pilot or exploratory studies, and major regulatory bodies have not approved BPC-157 for clinical use. Therefore, claiming it aids tissue recovery and gut health overstates the current state of scientific evidence.
- supports: Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. (Frontiers in pharmacology 2021) · cited 46x in the literature
"By simultaneously curing cutaneous and other tissue wounds (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, and rectovaginal) in rats, the potency of BPC 157 is evident." (abstract, passage verified)
pubmedfull study (doi) - context: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. (International journal of molecular sciences 2026) · cited 2x in the literature
"BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue... Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration" (abstract, passage verified)
pubmedfull study (doi)
TB-500 promotes tissue recovery and bone regeneration.
"TB-500, Thymosin Alpha, and SS-31. So, recovery and gut; more recovery because I had a tooth extraction a little while ago and I'm trying to regrow a bone in my face" (said at 1:39:48)
Preclinical in vitro and rodent studies indicate that thymosin beta-4 (and its synthetic derivative TB-500) has regenerative properties that can facilitate angiogenesis, wound healing, and fracture repair. However, these effects have not been demonstrated in clinical trials for bone regeneration or post-extraction healing in humans. A comprehensive review of emerging peptides in musculoskeletal medicine concluded that the claimed benefits of TB-500 remain unsubstantiated by clinical trials.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.